Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...
Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...
Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...
Victoza); and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 tirzepatide (Mounjaro, Zepbound). “This was a safety-related labeling change for the glucagon-like peptide 1 receptor ...